logo
Share SHARE
FONT-SIZE Plus   Neg

Curis Presents Data On PI3K And HDAC Inhibitor CUDC-907

Curis Inc. (CRIS) announced the presentation of data in a poster session at the American Association for Cancer Research or AACR Annual Meeting 2012 in Chicago, Illinois.

The poster presentation, titled "Antitumor Activity of CUDC-907, a Dual PI3K and HDAC Inhibitor in Hematological Cancer Models", was presented by Rudi Bao, M.D., Ph.D., Curis' Senior Director of Oncology.

The company noted that the poster presentation focused on CUDC-907's biologic activity in cell culture and animal models of various hematological cancers, with a particular focus on multiple myeloma and B-cell lymphoma. In in vitro and in vivo testing, CUDC-907 outperformed a first-in-class HDAC inhibitor as well as an investigational pan-PI3K (Class I) inhibitor given as a single agent or in a combination of both agents.

CUDC-907 also demonstrated enhanced antitumor activity in animal models of B-cell lymphoma and multiple myeloma when co-administered with standard of care agents used in the treatment of patients with these malignancies.

Furthermore, this poster showed that many commonly used in vivo models of B-cell lymphoma and multiple myeloma expressed various PI3K Class I isoforms, suggesting that a pan-PI3K inhibitor such as CUDC-907 may be of greater benefit in many cases than a PI3K inhibitor that is focused narrowly on one PI3K isoform.

The company stated that CUDC-907 showed greater biologic activity than a delta-specific investigational inhibitor in a number of hematological cancer cells in vitro, and showed greater growth-inhibitory activity in an animal model of non-Hodgkin's Lymphoma.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Time Warner Inc. (TWX) reported a profit for the fourth-quarter of 2015 that increased 19.4% from last year. But, quarterly revenues decreased about 6% from the prior year, due to a decline at Warner Bros., partially offset by increases at Home Box Office and Turner. The company increased its regular quarterly dividend by 15% to $0.4025 per share. Breakfast and snack food giant Kellogg Co. (K) continues to make great progress with its productivity initiatives. Hence, it remains confident in meeting its long-term targets for currency-neutral comparable net sales and operating profit growth in 2016 and beyond. However, negative currency translation impact that prevailed in the last few quarters is expected to continue in the fourth quarter. Dutch brewer Heineken NV reported higher profit and revenues in its fiscal 2015 with positive growth in Americas, Asia Pacific and Europe. Meanwhile, its Danish peer Carlsberg Group reported a significant loss annually, compared to prior year's profit, amid hefty charges as well as weak Europe performance. Both companies announced dividends, and expect organic growth in profit for fiscal 2016.
comments powered by Disqus
RELATED NEWS
Trade CRIS now with 
Follow RTT